Filing Flows › Health Care › Ironwood Pharmaceuticals (IRWD)
Ironwood Pharmaceuticals (IRWD) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Ironwood Pharmaceuticals (IRWD) Q3 2026 earnings results →
Q3 2026 Revenue up 9% year over year to $133M · 45¢ of every $1 of revenue kept as net profit · operating margin 70.0%
Ironwood Pharmaceuticals made $133M in Q3 2026 (+9% Y/Y). Operating margin 70.0%, net earnings $59.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $133.0M in Q3 2026, up 9% year over year and up 18% from the previous quarter.
Operating profit was $93.1M, a 70.0% margin (up 8.2 points year over year). Of the extra revenue versus Q3 2025, 161% reached operating profit, above the 62% margin then. Total costs fell 14% while revenue rose 9%. The fastest-growing cost line was Research & development (+26%). Net earnings were $59.8M, up 49% year over year. The effective tax rate was 31.7%.
Operating cash flow was $67.4M (up 42% year over year), 113% of net earnings. Non-cash charges added back $459K of depreciation and $4.3M of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $133M | +9% | 70.0% | $59.8M | $67.4M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $113M | +33% | 70.2% | $51.3M | $58.3M |
| Q1 2026 | 10-Q | May 7, 2026 | $107M | +159% | 68.1% | $40.8M | $5.1M |
| Q4 2025 | 10-K | Feb 26, 2026 | $47.7M | -47% | 14.3% | −$2.3M | $74.6M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $122M | +33% | 61.8% | $40.1M | $47.6M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $85.2M | -10% | 53.2% | $23.6M | −$15.1M |
| Q1 2025 | 10-Q | May 12, 2025 | $41.1M | -45% | -70.7% | −$37.4M | $20.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
About Ironwood Pharmaceuticals
We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases. LINZESS ® (linaclotide), our commercial product, is the first product approved by the United States Food and Drug Administration, or U.S. FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for the treatment, in the U.S., of irritable bowel syndrome with constipation, or IBS-C, in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation, or CIC, in adults, and functional constipation, or FC, in pediatric patients ages 6-17 years-old.
In its own words, from its 10-K, filed Feb 26, 2026.
Ironwood Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +9% against the peers' median +9%. Operating margin: 70.0% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Q3 2026 | $133M | +9% | 70.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Ironwood Pharmaceuticals 10-Q on SEC EDGAR · CIK 1446847 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns IRWD and who is buying
More on IRWD
- How Ironwood Pharmaceuticals makes money: revenue by segment
- Ironwood Pharmaceuticals next earnings date and what analysts expect
- Ironwood Pharmaceuticals stock forecast, price target and fair value
- Who owns Ironwood Pharmaceuticals stock: holders, funds and Congress trades
- Ironwood Pharmaceuticals guidance and outlook
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results